中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2014年
2期
168-170
,共3页
杨晓斌%孙涛%李欣%高广周%朱文娅
楊曉斌%孫濤%李訢%高廣週%硃文婭
양효빈%손도%리흔%고엄주%주문아
非糜烂性反流病%埃索美拉唑%马来酸曲美布汀%枸橼酸莫沙必利
非糜爛性反流病%埃索美拉唑%馬來痠麯美佈汀%枸櫞痠莫沙必利
비미란성반류병%애색미랍서%마래산곡미포정%구연산막사필리
Non-erosive reflux disease%Esomeprazole%Trimebutine%Mosapride
目的 探讨埃索美拉唑联合马来酸曲美布汀治疗非糜烂性反流病(NERD)的临床效果及复发情况.方法 将125例NERD患者应用计算机随机分为治疗组和对照组.治疗组62例,给予埃索美拉唑20 mg,每日2次口服;马来酸曲美布汀0.2g,每日3次口服.对照组63例,给予埃索美拉唑20mg,每日2次口服;枸橼酸莫沙必利5 mg,每日3次口服.疗程均为8周,并于停药后半年进行随访,比较两组临床疗效及复发情况.结果 治疗4周治疗组症状评价总有效率为75.8％ (47/62),高于对照组的57.1％ (36/63),差异有统计学意义(x2=4.879,P=0.027);治疗8周治疗组症状评价总有效率为95.2％ (59/62),高于对照组的84.1％ (53/63),差异有统计学意义(x2=4.083,P=0.043).治疗4周治疗组GERDQ评分有效率为72.6％ (45/62),高于对照组的52.4％(33/63),差异有统计学意义(x2=5.434,P=0.020);治疗8周治疗组GERDQ评分有效为93.5％(58/62),高于对照组的79.4％(50/63),差异有统计学意义(x2=5.350,P=0.021).停药半年后治疗组复发率为77.4％ (48/62),对照组复发率为81.0％ (51/63),差异无统计学意义(P =0.627).结论 埃索美拉唑与马来酸曲美布汀联合治疗NERD安全有效.
目的 探討埃索美拉唑聯閤馬來痠麯美佈汀治療非糜爛性反流病(NERD)的臨床效果及複髮情況.方法 將125例NERD患者應用計算機隨機分為治療組和對照組.治療組62例,給予埃索美拉唑20 mg,每日2次口服;馬來痠麯美佈汀0.2g,每日3次口服.對照組63例,給予埃索美拉唑20mg,每日2次口服;枸櫞痠莫沙必利5 mg,每日3次口服.療程均為8週,併于停藥後半年進行隨訪,比較兩組臨床療效及複髮情況.結果 治療4週治療組癥狀評價總有效率為75.8％ (47/62),高于對照組的57.1％ (36/63),差異有統計學意義(x2=4.879,P=0.027);治療8週治療組癥狀評價總有效率為95.2％ (59/62),高于對照組的84.1％ (53/63),差異有統計學意義(x2=4.083,P=0.043).治療4週治療組GERDQ評分有效率為72.6％ (45/62),高于對照組的52.4％(33/63),差異有統計學意義(x2=5.434,P=0.020);治療8週治療組GERDQ評分有效為93.5％(58/62),高于對照組的79.4％(50/63),差異有統計學意義(x2=5.350,P=0.021).停藥半年後治療組複髮率為77.4％ (48/62),對照組複髮率為81.0％ (51/63),差異無統計學意義(P =0.627).結論 埃索美拉唑與馬來痠麯美佈汀聯閤治療NERD安全有效.
목적 탐토애색미랍서연합마래산곡미포정치료비미란성반류병(NERD)적림상효과급복발정황.방법 장125례NERD환자응용계산궤수궤분위치료조화대조조.치료조62례,급여애색미랍서20 mg,매일2차구복;마래산곡미포정0.2g,매일3차구복.대조조63례,급여애색미랍서20mg,매일2차구복;구연산막사필리5 mg,매일3차구복.료정균위8주,병우정약후반년진행수방,비교량조림상료효급복발정황.결과 치료4주치료조증상평개총유효솔위75.8％ (47/62),고우대조조적57.1％ (36/63),차이유통계학의의(x2=4.879,P=0.027);치료8주치료조증상평개총유효솔위95.2％ (59/62),고우대조조적84.1％ (53/63),차이유통계학의의(x2=4.083,P=0.043).치료4주치료조GERDQ평분유효솔위72.6％ (45/62),고우대조조적52.4％(33/63),차이유통계학의의(x2=5.434,P=0.020);치료8주치료조GERDQ평분유효위93.5％(58/62),고우대조조적79.4％(50/63),차이유통계학의의(x2=5.350,P=0.021).정약반년후치료조복발솔위77.4％ (48/62),대조조복발솔위81.0％ (51/63),차이무통계학의의(P =0.627).결론 애색미랍서여마래산곡미포정연합치료NERD안전유효.
Objective To investigate the effect and recurrence of the esomeprazole combined with trimebutine on treatment for non-erosive reflux disease(NERD).Methods One hundred and twenty-five cases of patients with NERD were randomly divided into the treatment group (n =62) and the control group (n =63).Patients in treatment group were received the esomeprazole 20 mg,twice a day and trimebutine 0.2 g,3 times a day,in control group were received the esomeprazole 20 mg,twice a day and mosapride 5 mg,3 times a day.After 8 weeks treatment,6 months follow-up was conducted and the effects and recurrence were evaluated.Results The clinical curative rates at 4th and 8th weeks treatment in treatment group were 75.8％ (47/62) and 95.2％ (59/62),higher than that of control group (57.1％ (36/63),x2 =4.879,P =0.027 ; 84.1％ (53/63),x2 =4.083,P =0.043).The GERDQ curative rates at 4th and 8th weeks treatment in treatment group were 72.6％ (45/62),93.5％ (58/62) respectively,significantly higher than that of the control group (52.4％ (33/ 63),x2 =5.434,P =0.020 ; 79.4％ (50/63),x2 =5.350,P =0.021).The recurrence rates of 6 months followup were 77.4％ (48/62) in the treatment group and 81.0％ (51/63) in the control group,there was no significant difference between the two groups (P =0.627).Conclusion Esomeprazole combined with trimebutine is safe and effective treatment on non-erosive reflux disease,and the recurrence rates was lower than that in the control group.
